Gas6 and Soluble MerTK in Periodontal Diseases

April 9, 2026 updated by: nuray Ercan, Abant Izzet Baysal University

Evaluation of Gas6 and Soluble MerTK Levels in Gingival Crevice Fluid in Individuals With Periodontal Health, Gingivitis, and Periodontitis

This study aimed to investigate gingival crevicular fluid (GCF) and serum soluble MerTK (sMerTK) and Gas6 levels in periodontal health and disease. A total of 90 individuals, 30 patients with stage III grade B periodontitis, 30 with gingivitis and 30 periodontally healthy individuals were included. Whole-mouth and site-specific clinical periodontal parameters including probing depth, clinical attachment level, bleeding on probing, gingival index, plaque index were recorded. GCF and serum sMerTK and Gas6 levels were measured by enzyme-linked immunosorbent assay. Statistical analysis was performed by using non-parametric tests.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

90

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Bolu
      • Bolu, Bolu, Turkey (Türkiye), 14030
        • Recruiting
        • Bolu Abant Izzet Baysal University Faculty of Dentistry
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

This clinical study will be conducted on individuals who apply to the Department of Periodontology, Faculty of Dentistry, Abant İzzet Baysal University.

Description

Inclusion Criteria:

  • Individuals without systemic diseases that may affect periodontal tissues (such as cardiovascular diseases, atherosclerosis, immune system disorders, rheumatoid arthritis, obesity, cancer, and diabetes)
  • Individuals who have not used antibiotics within the last 3 months
  • Individuals not taking any medications known to affect periodontal tissues
  • Individuals without infectious diseases such as HIV, hepatitis B virus (HBV), or tuberculosis
  • Individuals with at least 16 natural teeth, excluding third molars
  • Individuals aged 18 years and older

Exclusion Criteria:

  • Pregnant or lactating individuals
  • Individuals who have received periodontal treatment within the last 6 months
  • Current smokers

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
periodontally healthy (H) group
Other: gingival crevicular fluid collection
Gingival crevicular fluid collection using sterile paper strips inserted into the gingival sulcus for 30 seconds from selected periodontal sites (healthy, gingivitis, and periodontitis) for biomarker analysis (Gas6 and sMerTK).
gingivitis (G) group
Other: gingival crevicular fluid collection
Gingival crevicular fluid collection using sterile paper strips inserted into the gingival sulcus for 30 seconds from selected periodontal sites (healthy, gingivitis, and periodontitis) for biomarker analysis (Gas6 and sMerTK).
stage III grade B periodontitis (P) group
Other: gingival crevicular fluid collection
Gingival crevicular fluid collection using sterile paper strips inserted into the gingival sulcus for 30 seconds from selected periodontal sites (healthy, gingivitis, and periodontitis) for biomarker analysis (Gas6 and sMerTK).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gas6 Levels in Gingival Crevicular Fluid
Time Frame: baseline
Quantitative measurement of Gas6 levels (pg/mL) in gingival crevicular fluid samples using enzyme-linked immunosorbent assay (ELISA), and comparison of these levels among periodontally healthy, gingivitis, and periodontitis groups.
baseline
Soluble MerTK (sMerTK) Levels in Gingival Crevicular Fluid
Time Frame: baseline
Quantitative measurement of soluble MerTK (sMerTK) levels (pg/mL) in gingival crevicular fluid samples using enzyme-linked immunosorbent assay (ELISA), and comparison of these levels among periodontally healthy, gingivitis, and periodontitis groups.
baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plaque Index
Time Frame: baseline
Measurement of plaque index (score) in participants with periodontal health, gingivitis, and periodontitis, and evaluation of its correlation with gingival crevicular fluid Gas6 and soluble MerTK levels.
baseline
Probing Depth
Time Frame: baseline
Measurement of probing depth (mm) in participants with periodontal health, gingivitis, and periodontitis, and evaluation of its correlation with gingival crevicular fluid Gas6 and soluble MerTK levels.
baseline
Clinical Attachment Loss
Time Frame: baseline
Measurement of clinical attachment loss (mm) in participants with periodontal health, gingivitis, and periodontitis, and evaluation of its correlation with gingival crevicular fluid Gas6 and soluble MerTK levels.
baseline
Gingival Index
Time Frame: baseline
Measurement of gingival index (score) in participants with periodontal health, gingivitis, and periodontitis, and evaluation of its correlation with gingival crevicular fluid Gas6 and soluble MerTK levels.
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Abant Izzet Baysal University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 25, 2026

Primary Completion (Estimated)

May 10, 2026

Study Completion (Estimated)

May 20, 2026

Study Registration Dates

First Submitted

April 2, 2026

First Submitted That Met QC Criteria

April 9, 2026

First Posted (Actual)

April 16, 2026

Study Record Updates

Last Update Posted (Actual)

April 16, 2026

Last Update Submitted That Met QC Criteria

April 9, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BAIBU-SBF-NE-02

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Periodontitis

Clinical Trials on gingival crevicular fluid collection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe